{
  "docId": "019de072-4935-7342-8528-4e6eca3fe5c7",
  "docSlug": "31ea92baba83669e6443d115d329d67b",
  "documentTitle": "AstraZeneca | Investor Presentation Deck | 53 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 29,
  "pageCount": 53,
  "prevPage": 28,
  "nextPage": 30,
  "slideType": "key_messages",
  "function": "present_framework",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "Uses a patient icon array to illustrate prevalence and a horizontal timeline/spectrum to map MOAs to disease severity.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de072-4935-7342-8528-4e6eca3fe5c7/29",
  "deckHref": "/decks/019de072-4935-7342-8528-4e6eca3fe5c7",
  "deckJsonHref": "/decks/019de072-4935-7342-8528-4e6eca3fe5c7.json",
  "deckAnchorHref": "/decks/019de072-4935-7342-8528-4e6eca3fe5c7#slide-29",
  "components": [
    {
      "bbox": {
        "h": 0.07,
        "w": 0.45,
        "x": 0.52,
        "y": 0.8
      },
      "kind": "callout",
      "text": "Building a strategic presence in amyloidosis",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8f21a377-432f-40f2-8c3f-e457aa989a68",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.45,
        "x": 0.05,
        "y": 0.38
      },
      "kind": "chart",
      "text": "Patient population visualization for Farxiga and Amyloidosis",
      "attrs": null,
      "subkind": "dot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f4bf8170-7f37-40b5-92b8-7deeec42f315",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.45,
        "x": 0.52,
        "y": 0.27
      },
      "kind": "diagram",
      "text": "Complementary MOAs needed in ATTR to address full spectrum of patient need",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "73805ee4-9756-4f7b-874f-c06bb283378b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.08,
        "y": 0.275
      },
      "kind": "paragraph",
      "text": "Leveraging strengths and expertise across Cardiovascular, Rare Disease",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8b2c172f-07c6-454d-948f-ac6bc4a23b97",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.02,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "1. Mohamed-Salem L et al. Int J Cardiol. 2018 Nov 1; 270:192-196. 2. Cucaden C, et al. J Nucl Cardiol. 2020 May 8 3. Quock, T. P., et al. Blood Adv.2018; 2(10):1046-1053; Internal epidemiological analysis: Mayo Stage IIIa + b 4. New York Heart Association (NYHA) Functional Classification. MoA = mechanism of acton.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eb726218-4d14-4f44-aade-f5b5feba7ea0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Cohesive commercial and development strategy across Cardiovascular and Rare Disease",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "beed7a23-e074-420a-9e3f-1d2c97329935",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Expanding beyond heart failure in amyloidosis",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "99dcaa84-083b-4348-8a8d-b9392c773819",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "strategic-alignment",
      "slug": null,
      "matchId": "55fa472a-5b6c-4e60-a497-f2e4a0cdec74",
      "evidence": "Mapping commercial strengths to disease spectrum",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}